Achieve Life Sciences Inc.
- Address
- 22722 29th Drive Southeast Ste 100
Sponsor Overview
Specializations
Smoking Cessation and Nicotine Dependence
Achieve Life Sciences Inc. concentrates its research efforts on developing innovative therapeutic solutions for individuals seeking to overcome tobacco dependence. The organisation's clinical programmes target the physiological and behavioural aspects of nicotine addiction, with particular emphasis on creating pharmacological interventions that address the complex mechanisms underlying smoking behaviour.
- Novel smoking cessation therapeutics
- Nicotine receptor modulation
- Behavioural addiction interventions
The company's research portfolio reflects a commitment to addressing substance use disorders through targeted pharmaceutical development, focusing on compounds that may alter the rewarding properties of nicotine consumption and facilitate sustained abstinence from tobacco products.
Central Nervous System Pharmacology
The organisation explores therapeutic approaches that interact with central nervous system pathways involved in addiction and reward mechanisms. Their investigational compounds are designed to modulate neurotransmitter systems that play critical roles in substance dependence, particularly those associated with dopaminergic and cholinergic signalling.
- Neurological pathway modulation
- Addiction neuroscience applications
- Receptor-targeted therapies
This research direction emphasises understanding the neurobiological foundations of addictive behaviours and translating these insights into clinically viable treatment options for patients struggling with tobacco use disorder.
Behavioural Medicine and Public Health
Achieve Life Sciences Inc. addresses significant public health challenges related to tobacco consumption, recognising smoking as a leading preventable cause of morbidity and mortality worldwide. Their therapeutic development programmes aim to provide effective pharmacological tools that complement existing smoking cessation strategies.
- Tobacco-related disease prevention
- Addiction treatment optimisation
- Patient-centred cessation support
The company's research contributes to the broader field of addiction medicine by investigating compounds that may improve quit rates and reduce relapse among smokers, ultimately supporting long-term health outcomes and quality of life improvements for individuals attempting to discontinue tobacco use.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A Four Way Crossover Thorough QT/QTc Study to Evaluate the Electrocardiographic Effects of Therapeutic and Supratherapeutic Doses of Cytisinicline in Healthy Smokers |  Portugal | Not Recruiting |
| Evaluation of Renal Impairment and Dialysis on Pharmacokinetics of Single 3 mg Cytisinicline Dose in Nicotine Addiction Patients | Portugal Spain | Not Recruiting |
| Phase 1 Study on Food Impact on Cytisinicline Bioavailability and Pharmacokinetics in Healthy Adult Smokers | Portugal | Not Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 7 sites across their trial portfolio.
Therapeutic Focus
- 1.Behavioral Disciplines and Activities2 trials20 other sponsors
- 2.Not possible to specify1 trial220 other sponsors
Partnered Research Centres
7 centres- Address
- Hospital Da Prelada 0 Floor And 3 rd Floor, Rua Sarmento De Beires 153, 4250-449 Porto
- Address
- Lugar De Sete Fontes S Victor, 4710-243 Braga
- Address
- Paseo De La Castellana 261, 28046 Madrid
- Address
- Calle Del Profesor Martin Lagos Sn, 28040 Madrid
- Address
- Calle De Diego De Leon 62, 28006 Madrid
- Address
- Rua Conceicao Fernandes S/n, 4434-502 Vila Nova de Gaia
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Achieve Life Sciences Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.